Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
FinMin seeks more time for PSBs to meet MPS norm

2018-07-19 freepressjournal.in
New Delhi : The finance ministry may approach markets regulator Sebi to seek relaxation on the minimum 25 per cent public shareholding norm for some state banks (PSBs).
INDIANB IOB 500116 UDBKL IDBI UBLS 532418 532814 532505 CNRYY 532388 SYNDIBANK 532276 532121 532483 UBLA UCOBANK CANBK DENABANK ANDHRABANK

0
PSU bank stocks surge up to 11% on capital infusion reports

2018-07-17 thehindubusinessline
PSU bank stocks today surged up to 11 per cent amid reports that the finance ministry is likely to infuse about Rs 10,000 crore within a few days in some state-owned lenders to help them meet regulatory capital requirement.
INDIANB IOB ALBK 532418 532814 CNRYY 532179 532388 PNJZY 532121 532483 532461 CRPKY 532480 PNB CORPBANK CANBK DENABANK ANDHRABANK

0
Canara Bank - Updates

2018-07-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532483 CANBK CNRYY

0
Canara Bank - Trading Window

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532483 CANBK CNRYY

0
FinMin seeks more time for PSBs to meet MPS norm

2018-07-16 freepressjournal.in
New Delhi : The finance ministry may approach markets regulator Sebi to seek relaxation on the minimum 25 per cent public shareholding norm for some state banks (PSBs).
INDIANB IOB 500116 UDBKL IDBI UBLS 532418 532814 532505 CNRYY 532388 SYNDIBANK 532276 532121 532483 UBLA UCOBANK CANBK DENABANK ANDHRABANK

0
Canara Bank - Updates

2018-07-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532483 CANBK CNRYY

1
D-Street Buzz: Bulls roar as RIL jumps 4%, hits record high; GMR Infra zooms 8%, PSU banks rally

2018-07-12 moneycontrol
Bulls have taken complete control of Dalal Street with the Indian benchmark indices up over 1 percent. The Nifty has jumped 127 points and is trading at 11,069 mark while the Sensex is trading higher by 423 points at 36,689, reaching a new record high.
IOC 500408 500325 HCTHY 532483 532480 500696 532281 BJJQY RLNIY SBAZ ALBK YYBKY 530965 530005 CNRYY BAJFINANCE HCLTECH 500180 KOTAKBANK TCS CANBK RELIANCE HINDUNILVR 533155 532856 TTNQY JUBLFOOD 532540 532187 532461 RIGD JBLWY HDFCBANK INDIACEM 500034 YESBANK UBNC INDUSINDBK KMBKY IBN 532648 ICICIBANK PNJZY HDB 532174 TATAELXSI PNB 500247 TIMETECHNO

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...